Decision Resources

Press Releases

  • Decision Resources Group’s Monique Levy Appointed to Google Healthcare Advisory Board

    August 19, 2015

    (August 19, 2015) – Burlington, MADecision Resources Group today announced that Monique Levy, vice president of digital innovation at Decision Resources Group, has been selected to join Google’s Healthcare Advisory Board. A recognized thought leader, analyst and strategist in the healthcare, media and technology space, Levy will provide key insights on the changing healthcare industry to advance the board’s mission.Read More

  • Focus on High-Growth Segments in the US and European Veterinary Orthopedic Implant Markets Imperative to Gain Market Share

    August 19, 2015

    (August 19, 2015) - Burlington, Mass. Decision Resources Group finds that the European veterinary orthopedic implant market is less penetrated relative to the market in the United States. The European market continues to be negatively impacted by the eurozone debt crisis, and despite a similar number of veterinarians practicing in both geographies, European veterinarians tend to be less specialized. Therefore, they have not yet adopted some of the new, premium-priced technologies, limiting market size in this geography.
    Read More

  • Significant Growth Expected Within The Lysosomal Storage Disorders Market

    August 11, 2015

    (August 12, 2015) - Burlington, Mass. Decision Resources Group forecasts that the number of lysosomal storage disorders (LSDs) with available treatments is set to double from eight in the base year of its forecast (2013) to sixteen by 2023. As a consequence, the value of the LSDs market is set to increase from $3.2 bn in 2013 to $5.9 bn in 2023. Additionally, the development of therapies with novel mechanisms of action will provide competition for traditional enzyme replacement therapy (ERT) for a number of LSDs.Read More

  • The Increasing Use of Ventricular Assist Devices Will Drive Cardiac Assist Device Market Growth in Europe

    August 7, 2015

    (August 11, 2015) - Burlington, Mass. Decision Resources Group finds that the cardiac assist device market will experience moderate growth through 2023. The overall market will be driven primarily by the expanding use of ventricular assist devices (VADs), which are being increasingly adopted with improving physician awareness and training, as well as, expanding indications for use. The total artificial heart (TAH) market will also expand rapidly because these products are one of the only options for bridging patients with biventricular failure to transplantation.Read More

  • Favorable Reimbursement and Novel Devices will Fuel Growth in the US Neurosurgery Device Market

    August 5, 2015

    (August 6, 2015) - Burlington, Mass. Decision Resources Group finds that the neurosurgery device market in the US will grow robustly over the next ten years, driven primarily by a strong reimbursement rate for neurosurgical procedures and the adoption of premium-priced devices. The introduction of novel technologies has invigorated this space by expanding the eligible patient population while moving the field toward less invasive procedures.Read More

  • The Long-Term Outlook for European Sports Medicine Device Markets Remains Positive, with Economic Recovery and Expanding Patient Populations Supporting Growth Through 2023

    July 29, 2015

    (July 29, 2015) - Burlington, Mass. Decision Resources Group finds that the sports medicine device market in Europe will continue to be hindered in the near term by unfavorable economic conditions across the Eurozone. On a longer timeline, however, the outlook is improved. Expanding populations of the elderly, obese, and physically active will increase the prevalence of osteoarthritic damage and sports-related injuries that require treatment via arthroscopy devices and orthopedic soft tissue solutions. Coupled with continuing economic recovery across Europe, market growth will reach a moderate level by 2023 with total revenues approaching $900 million in that year.

    Read More

  • Decision Resources Group Projects the US Market for Diabetes Care Devices To Be Valued at Over $22 Billion by 2023

    July 17, 2015

    (July 17, 2015) - Burlington, Mass. Decision Resources Group finds that the diabetes device market in the US will grow at a strong pace through 2023. Growth will be primarily driven by rapid expansion in the large insulin delivery device market as well as the continuous glucose monitoring (CGM) market which is currently underpenetrated in the US. By 2023, the US market for diabetes care devices will be valued at over $22 billion.


    Read More

  • The Antiepileptic Drug Topiramate Dominates First Line Prophylactic Treatment of Migraine, with Allergan’s Botox Exhibiting Growth in Later Lines

    July 16, 2015

    (July 16, 2015) - Burlington, Mass. – Decision Resources Group finds that, through analysis of U.S. longitudinal patient-level claims data, the antiepileptic drug (AED) topiramate (Ortho-McNeil/Janssen-Cilag’s Topamax; other brands; generics) captured the greatest patient share among prophylactic treatment-naive migraine patients across the first three lines of therapy.

    Read More

  • Similarities and Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management

    July 7, 2015

    (July 7, 2015) - Burlington, Mass. Decision Resources Group finds that there are similarities and differences in dialysis patient management in the U.S. versus the EU5. In 2015, based on information submitted by U.S. and EU5 nephrologists from approximately 1,870 dialysis patient charts combined, ESAs and phosphate binders are the most commonly used renal medications in dialysis patients; however, the use of IV iron differs considerably between the two regions.

    Read More

  • Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies

    July 6, 2015

    (July 2, 2015) - Burlington, Mass. Decision Resources Group finds that surveyed U.S. and European retinal specialists identify less frequent dosing as the highest unmet need in diabetic macular edema (DME), due to the burden on both patients and providers associated with monthly or semi-monthly anti-vascular endothelial growth factor (VEGF) injections, which are the current standard of care. The mid-stage compound, Allergan/Molecular Partners’ abicipar pegol, which is in development for dosing every two to three months, could help lessen dosing frequency and U.S. retinal specialists anticipate prescribing the product to a median 20 percent of their diagnosed DME patients. Respondents also ascribe moderate to high unmet need for DME therapies which have a greater effect on improving visual acuity than current DME treatments (anti-VEGF agents and the long-acting corticosteroid implants, Allergan’s Ozurdex and Alimera Sciences’ Iluvien).

    Read More

  • Surveyed Rheumatologists Report That Otezla’s Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options

    July 2, 2015

    (July 1, 2015) - Burlington, Mass. Decision Resources Group finds that the three most frequently cited advantages of Otezla are its oral administration, alternative mechanism of action, and favorable safety profile, as reported by surveyed rheumatologists. Otezla was the first oral therapy specifically approved and launched for the treatment of active psoriatic arthritis in the United States. The current standard of care includes conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), such as methotrexate and sulfasalazine, and nonsteroidal anti-inflammatory drugs (NSAIDs). DMARDs and NSAIDs are expected to remain first-line treatment for peripheral arthritis and axial disease manifestations, respectively, due in large part to reimbursement requirements that restrict the use of more effective biologics to refractory patients. Otezla is generally perceived to have a level of efficacy in-between conventional DMARDs and biologics. Likewise, surveyed rheumatologists are divided as to whether they are more likely to initially prescribe Otezla to patients that have failed conventional DMARDs or patients that have failed biologics.

    Read More

  • Interventional Cardiology Device Markets in Europe, Japan, Latin America, and the U.S. each have Unique Characteristics that Contribute to Market Dynamics

    June 25, 2015

    (June 25, 2015) - Burlington, Mass. – Decision Resources Group finds that interventional cardiology (IC) device market dynamics depend heavily on geography. The European market will undergo growth due to continued adoption of premium-priced devices in Western Europe and strengthening economies in Eastern Europe. Similarly, the Latin American market will grow over the next 10 years as the economies in the region improve and governments invest in healthcare. Conversely, the IC device markets in two of the most developed countries, the United States and Japan, will contract over the next 10 years due to rapidly eroding device prices and relatively flat procedure growth.

    Read More

  • Asia Pacific Laparoscopic Device Market Strongly Impacted by Economic Expansion, Domestic Manufacturing, and Varying Device Preferences

    June 17, 2015

    June 17, 2015 - Burlington, Mass. – Decision Resources Group finds that the laparoscopic device market in the Asia Pacific region—including Australia, China, India, and South Korea—will grow at a much stronger rate compared to the market in the US and Europe through 2023. Growth will be primarily driven by expansion in China and India, which are underpenetrated. Economic expansion, government investment in health care, and improving training will lead to the growing adoption of laparoscopic procedures in both of these markets. By 2023, the Asia Pacific market will be approximately one-third of the size of the US market.

    Read More

  • Economic Headwinds and Increasing Government Oversight Create New Challenges for Competitors in the Latin American Medtech Market

    June 12, 2015

    June 12, 2015 - Burlington, Mass. – Decision Resources Group finds that economic instability and fluctuating currencies have created numerous hurdles for medical device manufacturers in Latin America. Brazil and Argentina in particular are facing difficult economies, and both countries have felt the impact of slowing economic growth in China, a key export partner. The combination of a strong USD and slumping Latin American currencies has also created challenges for distributors because devices are purchased from manufacturers in USD but reimbursed in local currency; as these currencies fall, the value of the reimbursement paid to distributors decreases in relation to the USD price. As a result, it is expensive and increasingly unprofitable to import devices into Latin American countries.

    Read More

  • The Cancer Immunotherapy Market Will Capture Major-Market Sales of Over $13 Billion In 2023 and Will be Dominated by Immune Checkpoint Inhibitors

    June 4, 2015

    June 04, 2015 - Burlington, Mass. – Decision Resources Group finds that the cancer immunotherapy market will experience an impressive 29% annual growth over the forecast period and will reach $13.3 billion in 2023 across the seven major markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Growth will be fuelled by successive label expansions of Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo (nivolumab) and Merck & Co.’s Keytruda (pembrolizumab) in new cancer indications and/or patient populations and by the expected launches of eight novel cancer immunotherapies, including four immune checkpoint inhibitors and four therapeutic vaccines. Immune checkpoint inhibitors (totaling seven agents) will claim a staggering 91% share of the cancer immunotherapy market in 2023.

    Read More

View All